Hoth Therapeutics, INC 8-K filings

Hoth Therapeutics has entered into an agreement to sell up to $2.7 million of its common stock through an at-the-market offering.

Hoth Therapeutics has received a notification from Nasdaq for failing to maintain the minimum bid price of $1.00 per share, placing its listing at risk.

Hoth Therapeutics held its 2024 annual meeting, where shareholders re-elected all board members, ratified the appointment of Withum as auditor, and approved an increase in shares reserved under the 2022 equity incentive plan.

Hoth Therapeutics has amended its bylaws to clarify shareholder voting rights at company meetings, effective June 14, 2024.

Hoth Therapeutics has entered into an agreement for the immediate exercise of existing warrants, generating approximately $4.2 million in gross proceeds and issuing new warrants for future stock purchases.